Recent News

• 02.20.2025 - Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
• 02.20.2025 - Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
• 02.18.2025 - Aptose Announces Reverse Share Split
• 02.18.2025 - Aptose Announces Reverse Share Split
• 02.13.2025 - Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
• 02.13.2025 - Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
• 02.12.2025 - Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
• 02.12.2025 - Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Recent Filings

• 02.20.2025 - 8-K Current report
• 02.20.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 8-K Current report
• 02.18.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2025 - EX-99.1 EX-99.1
• 02.13.2025 - 8-K Current report
• 02.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.13.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 02.13.2025 - EX-99.1 EX-99.1